American Brivision (Holding) Corp (OTCMKTS:ABVC) shares traded down 0.7% during trading on Friday . The company traded as low as $2.82 and last traded at $2.85, 1,500 shares traded hands during trading. A decline of 25% from the average session volume of 2,007 shares. The stock had previously closed at $2.87.
Separately, ValuEngine upgraded American Brivision (Holding) from a “buy” rating to a “strong-buy” rating in a research report on Friday, January 3rd.
The company has a 50-day moving average price of $3.70 and a 200-day moving average price of $6.53.
American Brivision (Holding) (OTCMKTS:ABVC) last issued its quarterly earnings data on Monday, November 18th. The company reported ($0.07) earnings per share (EPS) for the quarter. The firm had revenue of $0.20 million during the quarter.
About American Brivision (Holding) (OTCMKTS:ABVC)
American BriVision (Holding) Corporation, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company's licensed products include ABV-1501, a combination therapy for triple negative breast cancer; ABV-1502, a combination therapy for solid tumors with Anti-PD1; ABV-1503, a combination therapy for chronic lymphocytic leukemia; ABV-1504 for depressive disorders; ABV-1505, a combination therapy for attention deficit hyperactivity disorder; BFC-1401, a vitreous substitute for vitrectomy; and Maitake combination therapy.
See Also: What is an overbought condition?
Receive News & Ratings for American Brivision (Holding) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Brivision (Holding) and related companies with MarketBeat.com's FREE daily email newsletter.